Analysis of HLA class I alterations in tumors: Choosing a strategy based on known patterns of underlying molecular mechanisms

Tissue Antigens

Volumn 69, Issue SUPPL. 1, 2007, Pages 264-268

  Cabrera, T ^a,b   Maleno, I ^a   Collado, A ^a   Lopez Nevot, M A ^a,b   Tait, B D ^c   Garrido, F ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

Author keywords

Cancer immunotherapy; Human leukocyte antigen class I alterations; Loss of heterozygosity; Tumor

Indexed keywords

HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER CELL; CHROMOSOME LOSS; CLINICAL PROTOCOL; COLORECTAL CARCINOMA; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; FOLLOW UP; GENE MUTATION; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR IMMUNITY;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MUTATION; NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 34247263417     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00777.x     Document Type: Conference Paper

References (15)

1. Boon T, Coulie PG, Van der Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2005: 24: 631-4.
2. Benitez R, Godelaine D, Lopez-Nevot MA et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998: 52: 520-9.
3. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveilance of altered HLA class I phenotypes in human. Immunol Today 1997: 18: 89-95.
4. Cabrera T, López-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003: 52: 1-9.
5. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001: 83: 117-58.
6. Ramal LM, Maleno I, Cabrera T et al. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 2000: 61: 1001-12.
7. Romero JM, Jimenez P, Cózar JM et al. Co-ordinated downregulation of the antigen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005: 113: 605-10.
8. Maleno I, Cabrera CM, Cabrera T et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004: 56: 244-53.
9. Mendez R, Ruiz-Cabello F, Rodriguez Tet al. Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother 2007: 56(1): 88-94.
10. Cabrera CM, Jiménez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI negative tumors. Tissue Antigens 2003: 61: 211-9.
11. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001: 19: 1211-20.
12. Jimenez P, Cabrera T, Mendez R et al. A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics 2001: 53: 606-10.
13. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998: 101: 2720-9.
14. Jain KK. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 2005; 4:645-50.
15. Samoylova TI, Morrison NE, Globa LP, Cox NR. Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anticancer Agents Med Chem 2006: 6: 9-17.